home / stock / plx / plx news

PLX News and Press, Protalix BioTherapeutics Inc. From 11/13/25

Stock Information
Company Name: Protalix BioTherapeutics Inc.
Stock Symbol: PLX
Market: NYSE
Website: protalix.com
Menu
PLX PLX Quote PLX Short PLX News PLX Articles PLX Message Board
Get PLX Alerts

News, Short Squeeze, Breakout and More Instantly...
PLX - Protalix BioTherapeutics GAAP EPS of $0.03 misses by $0.03, revenue of $17.67M misses by $0.2M

2025-11-13 06:53:09 ET More on Protalix BioTherapeutics Protalix: Speculative Buy On Promising Plant-Cell Platform And Elfabrio Ramp Protalix BioTherapeutics Q3 Earnings Preview Seeking Alpha’s Quant Rating on Protalix BioTherapeutics Historical earnin...
PLX - Protalix BioTherapeutics Reports Third Quarter 2025 Financial and Business Results

Protalix BioTherapeutics Reports Third Quarter 2025 Financial and Business Results PR Newswire Company to host conference call and webcast today at 8:00 a.m. EST CARMIEL, Israel , Nov. 13, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a ...

PLX - Protalix BioTherapeutics Q3 Earnings Preview

2025-11-12 11:03:56 ET More on Protalix BioTherapeutics Protalix: Speculative Buy On Promising Plant-Cell Platform And Elfabrio Ramp Protalix BioTherapeutics, Inc. (PLX) Q2 2025 Earnings Call Transcript Protalix signals $100M+ Elfabrio royalties by 2030 as Phase II P...

PLX - Protalix BioTherapeutics to Announce Third Quarter 2025 Financial and Business Results on November 13, 2025

Protalix BioTherapeutics to Announce Third Quarter 2025 Financial and Business Results on November 13, 2025 PR Newswire Company to host conference call and webcast at 8:00 a.m. EST CARMIEL, Israel , Nov. 6, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE ...
PLX - Chiesi Global Rare Diseases and Protalix BioTherapeutics Seek Re-examination from the EMA for the Negative Opinion for Elfabrio (pegunigalsidase alfa) Alternative Dosing Regimen of Every Four Weeks in the EU

PARMA, Italy and CARMIEL, Israel, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Chiesi Global Rare Diseases, a business unit of the Chiesi Group, and Protalix BioTherapeutics, Inc. (NYSE American: PLX), have requested a re-examination of the recent negative opinion issued by the Committee for Medicinal Produ...

PLX - PLX Investors Have Opportunity to Join Protalix BioTherapeutics, Inc. Fraud Investigation with the Schall Law Firm

The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Protalix BioTherapeutics, Inc. (“Protalix” or “the Company”) (NYSE: PLX ) for violations of the securities laws. The inves...

PLX - Levi & Korsinsky Launches Fraud Investigation on Behalf of Protalix BioTherapeutics, Inc. (PLX) Shareholders

New York, New York--(Newsfile Corp. - October 27, 2025) - Levi & Korsinsky notifies investors that it has commenced an investigation of Protalix BioTherapeutics, Inc. ("Protalix BioTherapeutics, Inc.") (NYSE American: PLX) concerning possible violations of federal securities laws. On October...
PLX - US Companies Moving the Markets, Morning edition
Fri, Oct 17, 2025 as of 10.00 am ET

A look at the top 10 most actives in the United States Rani Therapeutics Holdings Inc. (RANI) rose 158.0% to $1.215 on volume of 150,083,425 shares Direxion Daily Semiconductor Bear 3X Shares (SOXS) rose 3.9% to $4.175 on volume of 72,025,447 shares Bitfarms Ltd. (BITF) fell 8.5% to $4.83 o...

PLX - Chiesi Global Rare Diseases and Protalix Biotherapeutics Acknowledge CHMP Negative Opinion on Every Four Week Dosing Regimen of Elfabrio® (pegunigalsidase alfa) in the EU

PARMA, Italy and CARMIEL, Israel, Oct. 17, 2025 (GLOBE NEWSWIRE) -- Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people living with rare diseases, and Protalix BioTherapeutics, Inc. (NYSE American:PLX), a biopharmac...

PLX - Protalix BioTherapeutics to Present at Investor Summit Virtual

CARMIEL, ISRAEL / ACCESS Newswire / September 11, 2025 / Protalix BioTherapeutics, Inc. (NYSE American:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx ® plant cell-bas...
Previous 10 Next 10